Avidity Biosciences, Inc. (RNA) |
|
23.47 1.01 (4.5%)
|
01-27 16:00 |
|
Open: |
22.34 |
Pre. Close: |
22.46 |
|
High:
|
23.94 |
Low:
|
22.2 |
|
Volume:
|
810,882 |
Market Cap:
|
1,560(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:36 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 27.96  One year: 32.65 |
| Support: |
Support1: 20.17 Support2: 17.85 |
| Resistance: |
Resistance1: 23.94 Resistance2: 27.96 |
| Pivot: |
21.58 |
| Moving Average: |
MA(5): 22.83 MA(20): 21.4
MA(100): 16.97 MA(250): 16.74 |
| MACD: |
MACD(12,26): 1.5 Signal(9): 1.5  |
| Stochastic oscillator: |
%K(14,3): 87.9 %D(3): 88.5 |
| RSI: |
RSI(14): 64.5 |
| 52-week: |
High: 23.94 Low: 9.82 |
| Average Vol(K): |
3-Month: 1,988 (K) 10-Days: 682 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RNA ] has closed below upper band by 18.4%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
23.97 - 24.11 |
24.11 - 24.23 |
|
Low:
|
21.86 - 22.03 |
22.03 - 22.18 |
|
Close:
|
23.22 - 23.47 |
23.47 - 23.7 |
|
Company Description |
|
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. |
Headline News |
Wed, 25 Jan 2023
With new funding, Atomic AI envisions RNA as the next frontier in drug discovery - TechCrunch
Wed, 25 Jan 2023
Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating ... - Business Wire
Fri, 20 Jan 2023
New tool can accurately discover, quantify RNA molecules from error-prone long-read RNA sequencing data - News-Medical.Net
Fri, 20 Jan 2023
ESPRESSO: Robust discovery and quantification of transcript isoforms from error-prone long-read RNA-seq data - Science
Thu, 19 Jan 2023
"Pantranscriptome" Toolkit Analyzes RNA Sequencing Data ... - Genetic Engineering & Biotechnology News
Tue, 17 Jan 2023
Researchers produce first-ever toolkit for RNA sequencing analysis ... - University of California, Santa Cruz
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
66 (M) |
|
% Held by Insiders
|
4.281e+007 (%) |
|
% Held by Institutions
|
5.4 (%) |
|
Shares Short
|
7,030 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.6302e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
977 |
|
Return on Equity (ttm)
|
-24 |
|
Qtrly Rev. Growth
|
8.31e+006 |
|
Gross Profit (p.s.)
|
18.14 |
|
Sales Per Share
|
-51.84 |
|
EBITDA (p.s.)
|
-1.13407e+008 |
|
Qtrly Earnings Growth
|
-3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-123 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.46 |
|
Price to Cash Flow
|
-0.14 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
6.51e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
